Glucagon Delivery via Enzymatic Hydrogel pH Switch
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucose-responsive materials for diabetes management often lead to hypoglycemia risks due to excessive insulin activity, necessitating conservative insulin dosing and chronic health complications to avoid acute hypoglycemia, highlighting the need for improved precision in blood glucose control.
Innovation Solution
Development of a peptide-based hydrogel system that utilizes glucose oxidase (GOx) to stabilize glucagon delivery, releasing glucagon only when glucose levels are low, thereby preventing hypoglycemia while maintaining stability during normal glucose conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin is used to manage blood glucose levels, then hyperglycemia can be controlled, but the risk of hypoglycemia increases
Solution Approach 1:
The patent applies preliminary anti-action by incorporating glucagon (which raises blood glucose) into the hydrogel system alongside insulin. When hypoglycemia occurs, the glucagon is released to counteract the excessive insulin effect, thereby preventing the harmful outcome while maintaining the beneficial glucose-lowering action of insulin.
Solution Approach 2:
The hydrogel system acts as an intermediary that mediates between insulin and glucagon release. It uses glucose oxidase to sense glucose levels and triggers selective release of either insulin or glucagon based on whether glucose levels are high or low, thereby mediating the overall blood glucose control while minimizing hypoglycemia risk.
2Object-affected harmful factors
If conservative insulin dosing is used to avoid hypoglycemia, then acute hypoglycemic events are reduced, but chronic health complications from blood glucose instability increase
Solution Approach 1:
The patent applies dynamics by creating a dynamic release system where the hydrogel responds to real-time glucose levels. The system transitions between releasing insulin (when glucose is high) and releasing glucagon (when glucose is low), providing adaptive control that optimizes both acute safety and chronic health outcomes.
Solution Approach 2:
The system implements feedback control through glucose oxidase, which continuously monitors glucose levels and triggers appropriate hormone release. When glucose drops below a threshold, the system detects this and releases glucagon to raise glucose back to normal levels, creating a closed-loop feedback mechanism that prevents both hypoglycemia and hyperglycemia.
3Measurement precision
If glucose-responsive release strategies are implemented, then precision in blood glucose control is improved, but system complexity increases
Solution Approach 1:
The patent applies parameter changes by utilizing pH changes as the triggering mechanism for drug release. Glucose oxidase generates protons that lower the local pH, and this pH change triggers the release of either insulin or glucagon from the hydrogel, providing precise control through a simple parameter change rather than complex mechanical or electronic systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively limits the onset and severity of hypoglycemia by controlled glucagon release, demonstrating improved glucose management and reduced risk of severe hypoglycemic events in diabetic models.
Implementation Method 1
GOx catalyzes the conversion of one molecule of D-glucose into glucono-δ-lactone and H2O2, with the former hydrolyzing to gluconic acid
Implementation Method 2
the former hydrolyzing to gluconic acid
Implementation Method 3
at a pH of about 5, the peptide of formula (I) self-assembles to form a hydrogel
Implementation Method 4
The construction of biomaterials and drug delivery devices from supramolecular interactions offers routes to endow stimuli-responsivity using tunable non-covalent associations
Implementation Method 5
at a pH of about 7, the hydrogel disassembles
Data Source
AI summary
Described herein are glucose-stabilized materials for glucose-responsive delivery of glucagon or a glucagon analogue to combat hypoglycemia and related disorders. Exemplary glucose-stabilized materials of the present invention include hydrogels comprising glucagon or a glucagon analogue and a peptide. Enzymatic control of molecular self-assembly and hydrogelation described herein enables encapsulation and glucose-responsive delivery of a therapeutic to address low glucose.